Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.
ONCOLOGY® Companion, Volume 39, Supplement 10
Experts discussed how treatment should be sequenced for patients with small cell lung cancer who have brain metastases, highlighting recent clinical trial advancements and safety considerations.
Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.
Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.
Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
2
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
3
Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma
4
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
5
